AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Safety Study of AZD5672 in Renally Impaired Subjects
Phase 1
Completed
- Conditions
- Renal Impairment
- Interventions
- Drug: AZD5672
- First Posted Date
- 2008-07-15
- Last Posted Date
- 2009-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00715702
- Locations
- 🇩🇪
Research Site, München, Germany
CARE - Quality Improvement in Asthma Secondary Prevention in Primary Care, Through Delegation of Consultations to the Nurse.
Completed
- Conditions
- Asthma
- First Posted Date
- 2008-07-14
- Last Posted Date
- 2011-03-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2122
- Registration Number
- NCT00714038
- Locations
- 🇩🇰
Research Site, Vojens, Denmark
Formulation and Food Effect Study of AZD1386 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Pharmacokinetics
- Interventions
- Drug: AZD1386
- First Posted Date
- 2008-07-14
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT00714337
CARE - Quality Improvement in Cardiovascular Secondary Prevention in Primary Care, Through Delegation of Consultations to the Nurse.
Completed
- Conditions
- Cardiovascular Disease
- First Posted Date
- 2008-07-14
- Last Posted Date
- 2012-01-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2193
- Registration Number
- NCT00713960
- Locations
- 🇩🇰
Research Site, Vivild, Denmark
🇩🇰Research site, Kobenhavn V, Denmark
A Proof of Concept and Dose Ranging Study in Patients With Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2008-07-11
- Last Posted Date
- 2011-10-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 373
- Registration Number
- NCT00713544
- Locations
- 🇺🇦
Research Site, Simferopol, Ukraine
Relative Bioavailability Study in Healthy Male Subjects for ZD4054 (Zibotentan) Immediate Release Tablets.
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: ZD4054
- First Posted Date
- 2008-07-11
- Last Posted Date
- 2010-11-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT00713791
- Locations
- 🇺🇸
Research Site, Philadelphia, Pennsylvania, United States
Multiple Ascending Doses (MAD) of AZD3199 Given Once Daily as Inhaled Formulation Via Turbuhaler to Healthy Men
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: AZD3199Drug: Placebo
- First Posted Date
- 2008-07-11
- Last Posted Date
- 2014-04-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT00713271
- Locations
- 🇸🇪
Research Site, Lund, Sweden
Four-period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (Zibotentan) (10mg and 30mg) on QTc Interval
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-07-11
- Last Posted Date
- 2010-09-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00713336
- Locations
- 🇬🇧
Research Site, Macclesfield, United Kingdom
Pharmacokinetic Interaction Between AZD3480 and Donepezil
- First Posted Date
- 2008-07-11
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 33
- Registration Number
- NCT00713765
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
An Interaction Study With Digoxin and AZD1305
- First Posted Date
- 2008-07-10
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT00712465
- Locations
- 🇸🇪
Research Site, Göteborg, Sweden
© Copyright 2025. All Rights Reserved by MedPath